Durabolin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Durabolin

Property Description
Active ingredient Nandrolone Phenylpropionate
Form Injectable solution
Pharmacological class Anabolic-androgenic steroid (AAS)
Common purpose Counteracting muscle and tissue wasting
Origin Synthetic hormonal preparation

The medicine commonly referred to as Durabolin is an injectable solution containing the active substance Nandrolone Phenylpropionate. This core compound is classified as an anabolic-androgenic steroid (AAS), a group of synthetic hormonal preparations structurally derived from testosterone. The structure of Nandrolone, a 19-nortestosterone derivative, is clinically recognized for providing a high ratio of anabolic (tissue-building) to androgenic effects. This specific formulation, based on the Phenylpropionate ester, serves as a differentiating factor, marking it as a relatively short-acting injectable Nandrolone compound.

The Preparation Type and Physical Form

Nandrolone Phenylpropionate is manufactured as an oil-based solution designed exclusively for administration via intramuscular injection. This preparation method is necessary because the compound would be rapidly deactivated by first-pass metabolism if taken orally, necessitating an alternate route to ensure systemic distribution. The use of the Phenylpropionate ester defines its release profile, resulting in a quicker onset and shorter duration of effect compared to the long-acting ester variation, Nandrolone Decanoate. This difference in the ester component is the primary distinguishing feature within the pharmaceutical variants of Nandrolone.

General Purpose: Promoting Tissue Restoration

The overall therapeutic purpose of this medication focuses on its clinically established capacity to promote tissue building and effectively counteract severe catabolic states within the body. The compound achieves this by acting as an androgen receptor agonist, which stimulates protein synthesis and helps sustain a positive nitrogen balance in muscle and bone tissues. This medication is typically used in clinical settings to support patients who require the restoration of muscle mass and body weight after experiencing profound illness or injury.

What side effects are possible with Durabolin?

Possible side effects and safety information

The official safety information for Nandrolone Phenylpropionate is structured around its effects as an anabolic-androgenic steroid, primarily addressing risks by the affected body system and patient group. While a universal frequency ranking for all adverse reactions is not consistently provided, the safety profile is documented by System-Organ Class and duration of exposure.

System-Organ-Class Effects

Adverse reactions are documented across several physiological systems. In the Genitourinary System, risks include virilization (masculinization) in women and the inhibition of testicular function and oligospermia in men. Effects on the Skin and Subcutaneous Tissue include acne and hirsutism (increased hair growth). Changes are also noted in the Metabolism and Nutrition system, such as fluid retention (edema) and alterations in serum lipid profiles (decreased HDL, increased LDL).

Serious Adverse Reactions

The regulatory documents highlight risks of serious, clinically significant adverse events, particularly associated with prolonged or chronic administration. These include the potential for severe Hepatic System effects, such as the development of liver tumors (hepatic neoplasms) and blood-filled cysts (peliosis hepatis). Irreversible virilization, such as voice deepening in women, is also documented as a risk.

Population-Specific Safety Considerations

Specific safety statements are documented for certain populations. Women must be monitored for signs of virilization. Prepubertal patients require periodic monitoring of bone age to assess the risk of premature closure of growth centers, which can compromise final adult height. Caution is also required in patients with pre-existing cardiac, renal, or hepatic disease due to the risk of fluid retention and hepatic complications.

Use is restricted in individuals with severe hepatic impairment due to safety concerns.

Overdose and Emergency Response

The official regulatory description of overexposure to Durabolin (Nandrolone Phenylpropionate) primarily focuses on the consequences of chronic over-administration at doses exceeding therapeutic guidelines.

Documented Overdose Manifestations

Chronic overexposure may present with androgenic effects, which include virilisation (such as deepening of the voice, hirsutism, and clitoral enlargement) in female patients, and priapism (prolonged erection) in male patients. Hematological changes, specifically polycythaemia (increased red blood cell mass), are also documented manifestations of excessive exposure in regulatory sources.

When to Seek Immediate Medical Help

Overexposure is associated with the potential for severe, life-threatening outcomes, including hepatic neoplasms (liver tumors) and peliosis hepatis, as well as an increased risk of serious cardiovascular events like heart attack or stroke. Immediate medical attention is required for any suspicion of these severe complications.

Regulatory instructions mandate the prompt discontinuation of the drug upon the observation of virilisation signs in women to prevent potentially irreversible changes. No specific antidote is known for this compound; therefore, management procedures are limited to providing symptomatic and supportive treatment. Due to the systemic risks of overexposure, periodic monitoring of blood parameters, including haemoglobin and haematocrit, and liver function tests are required to manage long-term complications.

Therapeutic Uses of Durabolin

Durabolin (nandrolone phenylpropionate) is applied in clinical settings for several core therapeutic areas where supportive symptomatic assistance is needed across conditions marked by increased physiological stress. This medication is commonly used to help manage specific, physically challenging conditions that result in noticeable symptoms.

The therapeutic domains of use include addressing symptoms related to wasting conditions, providing supportive management for bone stability, and offering assistance for symptoms related to systemic imbalance.

In these contexts, Durabolin helps address symptom clusters that may become intense or disruptive. This assistance provides support that helps ease the overall symptom burden and may assist with maintaining functional stability. It is often used during phases when symptoms become more noticeable, offering supportive relief when they interfere with routine activities.

“It is relevant when short-term symptomatic assistance is needed to help patients cope more steadily with difficult episodes.”


Quick Fact: Relevant for Easing Physical Discomfort


Key Symptomatic Areas

Durabolin is applied in domains where additional symptomatic support is needed, addressing groups of symptoms that may become intense or disruptive in contexts such as wasting, skeletal fragility, and fatigue related to systemic imbalance.

Regulatory References

  1. NPS MedicineWise overview

Eligibility and Restrictions for Use

Official Population Eligibility for Durabolin (Nandrolone Phenylpropionate)

Official regulatory documents define strict limitations on who can and cannot use this medicine, based on absolute prohibitions and mandatory cautionary restrictions.


Absolute Contraindications

Use of Durabolin is strictly prohibited for several specific patient groups:

  • Pregnant women (Pregnancy Category X), due to the high risk of fetal masculinization.
  • Male patients with known or suspected carcinoma of the prostate or breast, as the medication may stimulate tumor growth.
  • Female patients with breast cancer and hypercalcemia.
  • Individuals with known hypersensitivity to the active substance or excipients (e.g., peanut oil).

Conditional Use and Restricted Populations

Use is allowed only with close medical supervision and required monitoring for the following populations:

  • Pediatric patients (Children/Adolescents): Use is restricted due to the risk of premature epiphyseal closure (stunted growth) and must be monitored by regular X-ray examinations.
  • Older Adults (Geriatric Patients): Close monitoring is required due to an increased risk of prostatic issues.
  • Patients with severe hepatic, cardiac, or renal insufficiency: Caution is required due to the risk of fluid retention (edema). Use is also restricted for patients with diabetes mellitus, epilepsy, or migraine.

What should I know about interactions with other medicines?

The interaction profile of Durabolin (Nandrolone Phenylpropionate) is defined by pharmacodynamic and exposure-modifying effects with several categories of medicinal products, as documented in official government prescribing information.

Official Interaction Statements

  • Oral Anticoagulants: Co-administration with agents such as Warfarin or Acenocoumarol increases the sensitivity to the anticoagulant effect. This interaction may result in a higher Prothrombin Time (PT) and International Normalized Ratio (INR).
  • Antidiabetic Agents: Nandrolone may increase the hypoglycemic activities of antidiabetic agents, including Insulin and oral sulfonylureas. This suggests an additive effect on lowering blood glucose.
  • Adrenal Steroids and ACTH: The concomitant use of adrenal steroids or Corticotropin (ACTH) may add to the risk or severity of edema (fluid retention).
  • Hepatic Enzyme Inducers: Certain medicines known to increase liver enzyme activity, such as Rifampicin or Phenytoin, may potentially decrease the therapeutic effect of Nandrolone.

Drug/Laboratory Test Interactions

Anabolic steroid therapy is known to affect certain laboratory results. It may cause a decrease in Thyroxine-Binding Globulin (TBG), which can lead to decreased total T4 serum levels, although free thyroid hormone levels generally remain unchanged. The medicine may also cause an increase in prothrombin time.

Population-Specific Interaction Notes

Regulatory cautions specifically note that the risk of edema is heightened in patients with underlying cardiac, renal, or hepatic disease when co-administered with corticosteroids or ACTH. The label specifies monitoring requirements for INR and blood glucose when these interactions are relevant. The official profile does not specify mandatory time-separation rules for administration.

Mechanism of Action

Durabolin (nandrolone decanoate) is an anabolic-androgenic steroid that exerts its effects primarily through two key mechanistic domains.

Androgen Receptor Agonism

Durabolin acts as an agonist by binding to the androgen receptor (AR), a nuclear receptor found in various tissues, including muscle and bone. This binding event initiates a cascade where the activated receptor complex translocates into the cell nucleus, binding to specific DNA segments (androgen response elements) to regulate gene transcription. This mechanism modulates pathways that promote protein synthesis and the regulation of genes involved in tissue remodeling.


Regulation of Hematopoietic Factors

A distinct mechanistic domain involves the regulation of erythropoietic stimulating factors. Durabolin affects systems where specific mediators control blood cell production, notably by stimulating the production and release of erythropoietin in the kidney. This pathway modulation results in the physiological consequence of increased red blood cell production and total red cell mass.

Dosage and Administration Information

How to Use Durabolin

Durabolin (Nandrolone Phenylpropionate) is used according to a standardized protocol, focusing exclusively on administration and dosage. The medicine is an oil-based solution that must be administered solely by deep intramuscular injection by a trained healthcare professional. This requirement for medical supervision is a mandatory procedural element of its use.

Official Dosing and Frequency

Instruction Detail
Route of Administration Deep intramuscular injection only.
Dosing Schedule Typical adult dose is 25 mg to 50 mg.
Frequency and Timing Once every week.

The 25 mg to 50 mg dosage range is prescribed for conditions like general negative nitrogen balance. The once every week frequency is consistent with the established duration of action for the Phenylpropionate ester. Administration is independent of meals and drinks.

Procedural and Course Constraints

The total duration of use is not fixed but is determined by the patient’s clinical response to treatment, with therapy generally intended to be intermittent rather than continuous. The treatment is defined as adjunctive therapy, which mandates that the patient must also maintain adequate protein and caloric intake for the medication to be effective. For the handling of a missed dose, official guidance strictly states that the patient must not inject a double dose to compensate.

Recent Clinical Evidence

Research evidence / Overview of studies for Durabolin

Evidence for Use in Wasting Conditions and Tissue Restoration

Research has explored the compound in studies of patients experiencing involuntary muscle loss, a manifestation often described as a condition marked by functional limitations. Research exploring this area primarily uses short-term Randomized Controlled Trials (RCTs) and controlled studies. These investigations focused on populations of adults with conditions associated with acute or disruptive episodes of muscle wasting, including those linked to chronic illnesses. Findings describe patterns observed in these studies where shifts in Lean Body Mass (LBM) and body weight measurements were reported in the study groups. Certainty remains low regarding the maintenance of muscle mass after the initial short-term treatment period.


Evidence for Use in Anemia and Bone Support

Research has examined chronic kidney disease-related anemia, with evidence derived from Systematic Reviews and Meta-Analyses of older clinical trials. These studies explored whether the compound was associated with changes in hematological parameters, such as hemoglobin concentration and red cell mass. However, the evidence for this application is largely historical, and sample sizes were modest in the combined trials.

Studies have historically examined the compound in postmenopausal osteoporosis, with studies primarily measuring Bone Mineral Density (BMD). Findings related to this application are historical, as research has evolved toward newer treatment modalities. Limited information for long-term outcomes is available for this application.


Studies in Severe Catabolic States and Functional Recovery

More recent Phase II Pilot RCTs and ongoing multicenter study protocols have examined the compound in patients recovering from severe catabolic stress, such as those with deconditioning following a long stay in an intensive care unit (ICU) or after major orthopedic surgery. These trials monitored functional recovery markers, including the time measured to achieve milestones like walking. One randomized trial involving a specific elderly post-operative group described observations that did not include significant differences in functional outcomes. Reported findings generally indicate the need for further, larger-scale research exploring functional outcomes.


Research Gaps and Remaining Uncertainty

The research available for this compound presents limitations characterizing evidence gaps. The evidence quality varies across studies, with many trials being small or conducted decades ago. Comparative evidence is lacking against contemporary treatments for many of the studied indications. Follow-up durations were limited in many studies, and it appears to be uncertain how the observed short-term changes translate into long-term health outcomes.

Key Studies & References

  1. Nandrolone Phenylpropionate: Mechanism of action, Pharmacokinetics, Metabolism and Side Effects
  2. Anabolic steroids for chronic kidney disease-related anemia in the era of erythropoiesis-stimulating agents: A systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Durabolin (FAQ)

Q: What is Durabolin actually used for according to health regulators?

According to official regulatory documents, Durabolin is approved to treat specific medical conditions, primarily certain forms of anemia. Its therapeutic purpose is also to promote tissue building and encourage weight gain in patients who have experienced severe involuntary weight loss due to major surgery, trauma, or chronic infection. This function helps the body counteract severe catabolic (breaking down) states.

Q: How quickly can I expect a change after starting Durabolin?

Durabolin contains the Phenylpropionate ester, which is described in official product information as a relatively short-acting compound. This characteristic means its pharmacological profile is associated with a relatively quick onset of action. Its duration of action is shorter compared to the long-acting Decanoate ester, which is why the medicine is typically administered weekly.

Q: Does Durabolin stay in the body for a long time?

Due to the Phenylpropionate ester component, Durabolin is classified as a short-acting Nandrolone compound. Its pharmacological profile is intended to allow for a weekly dosing schedule, which helps maintain consistent therapeutic levels in the body over that time frame.

Q: Is Durabolin a controlled substance?

Yes, official regulatory agencies, such as the DEA in the United States, classify Nandrolone products, including Durabolin, as a Schedule III controlled substance. This classification is due to the compound belonging to the class of anabolic-androgenic steroids (AAS), a group of synthetic hormonal preparations.

Q: Are there specific food or drink items to avoid while taking Durabolin?

Official administration guidance states that the injection itself can be administered independently of meals and drinks. The official documents note that the treatment is defined as adjunctive therapy, meaning adequate protein and caloric intake are required for the medication to be effective.

Q: Do studies suggest Durabolin is used in both men and women?

Studies and official documentation indicate that the medicine is used in both men and women for its approved purposes. The regulatory documents, however, detail specific adverse effects and mandatory monitoring requirements that are unique to each sex.

Q: Is Durabolin considered an older or newer drug?

Evidence indicates that the compound is considered historical in the context of research for certain conditions, such as postmenopausal osteoporosis. The studies examining its use for these older indications are often derived from clinical trials conducted decades ago.

Q: Can people with kidney conditions use Durabolin?

Caution is specifically required for patients who have severe renal (kidney) insufficiency, according to official labeling. This caution is due to the potential for fluid retention, or edema. Official eligibility criteria describe that use is allowed only when under close medical supervision and required monitoring.

Q: What happens if I stop taking Durabolin suddenly?

Official prescribing information does not list specific acute physical withdrawal symptoms upon cessation. The official product information states that therapy is generally intended to be intermittent rather than continuous. Discontinuation is addressed as part of the established treatment protocol.

Q: Are there specific blood tests required before starting Durabolin?

Official documents specify that liver function tests, serum lipid profiles, and blood cell counts are examples of laboratory tests that are commonly performed. These tests are done both before beginning treatment and periodically during the course of therapy.

Q: How often are the side effects of Durabolin reported?

Official drug documentation and regulatory safety reports state that a universal frequency ranking (such as common, uncommon, or rare) is not consistently provided for all the reported adverse reactions of this product.

Q: Does Durabolin affect mood or mental state?

Official documentation for anabolic steroids may mention effects on the central nervous system. These documented effects can include potential changes to mood, increased irritability, and aggression.

Q: What are the legal prescribing conditions for Durabolin?

Due to its controlled substance classification, the medicine requires a valid prescription from a licensed healthcare provider for its legal acquisition and use. It is classified as a prescription-only medicine in all major regulatory regions.

Q: Is Durabolin available over the counter in any country?

No, the medication is categorized as a prescription-only medicine across all major regulatory regions, including the United States. This restriction is due to its classification as an anabolic-androgenic steroid and its controlled substance status.

Q: Do official prescribing documents mention anything about long-term use?

Official documents advise that therapy should generally be intermittent rather than continuous. Serious safety risks, such as the potential for liver tumors and irreversible virilization (masculinization), are highlighted as risks associated with prolonged or chronic administration.

Q: Can Durabolin affect the results of athletic drug tests?

The medicine is an anabolic steroid, and its use is strictly prohibited by many international sports organizations. Official warnings confirm that use of the medicine can result in a positive athletic drug test for performance-enhancing substances.

Q: What happens to the body's natural hormones when taking Durabolin?

Regulatory information indicates that in men, the medicine can cause inhibition of normal testicular function and oligospermia (a reduced sperm count). Changes in libido (sex drive) have also been documented in both men and women.

Q: Is Durabolin commonly used to treat osteoporosis?

Research into this specific application, such as in postmenopausal osteoporosis, is largely considered historical. Official evidence indicates that research has since evolved toward newer, more contemporary treatment modalities for this bone condition.

Q: Do experts consider Durabolin a high-risk medication?

Regulatory documents list several severe adverse effects, including the potential for life-threatening liver problems, and contain absolute prohibitions for high-risk populations. This indicates that serious safety concerns must be closely managed throughout the treatment course.

Q: What does 'contraindication' mean in the context of Durabolin?

According to standard medical terminology used in official documents, a contraindication is a condition or factor that absolutely forbids a certain medical treatment. The official definition states that treatment should be withheld when a contraindication is present, as using the medicine could cause potential harm or increased risk.

Q: Is there research on Durabolin's use outside of its main approved conditions?

Research protocols have examined the compound in specific areas outside of its primary indications, according to official documents. This includes studies on patients recovering from severe catabolic stress after major surgery or prolonged intensive care.

Q: Does Durabolin impact blood pressure?

The medicine is known to cause fluid retention, known as edema, which is listed as an adverse effect. This fluid retention may indirectly affect blood pressure in individuals who are susceptible. Therefore, official documents note that caution is advised for patients with pre-existing cardiac or renal conditions.

Q: Are the safety warnings for Durabolin very strict?

The official safety warnings are extensive and strict. The medicine includes absolute prohibitions for several high-risk groups and requires mandatory close monitoring for populations such as women, children, and older adults.

Q: What does the research say about Durabolin and heart health?

Regulatory documents confirm the medicine is known to alter serum lipid profiles, specifically by decreasing 'good' (HDL) cholesterol and increasing 'bad' (LDL) cholesterol. Additionally, the risk of fluid retention may increase, requiring caution in those with pre-existing cardiac disease.

Q: What does the term 'androgenic effects' mean regarding Durabolin?

Androgenic effects refer to the development or enhancement of male characteristics, according to official clinical pharmacology definitions. The manifestation of these effects in patients, particularly women, can include virilization symptoms like voice deepening and increased hair growth.

Q: Does Durabolin have a black box warning in the US?

FDA documentation highlights serious warnings regarding the potential for abuse and risks of hepatic (liver) system effects. This type of severe safety caution is consistent with the risks that are often addressed by a Black Box Warning in the US labeling system.

Q: Are there common signs of too much Durabolin in the body?

Signs of excessive exposure would typically manifest as an immediate worsening of the known adverse effects that are already outlined in official documentation. This could include clear signs of virilization in women or severe and noticeable fluid retention (edema).

How should Durabolin be stored and disposed of?

How to Store and Dispose of Durabolin (Nandrolone Phenylpropionate)

The storage and disposal of Durabolin injection must adhere strictly to official regulatory requirements to maintain product stability.

Official Storage Conditions

Requirement Specific Rule
Temperature Store below 30 C (86°F); Do not refrigerate or freeze.
Protection Protect from light and store in the original package.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Any unused medicinal product or waste material must be disposed of according to local requirements. The medicine should not be thrown away via wastewater or household trash. Following local pharmaceutical waste protocols ensures proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Durabolin found in:

A-Z Index: